Nexalin Expands Peer-Reviewed Neuroimaging Data Validating DIFS™ Technology
Event summary
- Nexalin Technology, Inc. highlighted peer-reviewed clinical research validating its DIFS™ technology across multiple neurological and psychiatric conditions.
- Recent studies span insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, and ADHD.
- Objective normalization of abnormal brain activity was demonstrated through advanced neuroimaging techniques like MRI, fMRI, MEG, EEG, and PET.
- A randomized, double-blind, sham-controlled trial published in Molecular Psychiatry showed normalization of abnormal gamma-frequency brain activity.
- Nexalin’s technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks.
The big picture
Nexalin’s expanding body of peer-reviewed research positions its DIFS™ technology as a leader in evidenced-based non-invasive brain stimulation. The company’s focus on objective neuroimaging data differentiates it from competitors relying on surface-level stimulation. As mental health disorders increasingly recognized as disorders of brain network regulation, Nexalin’s technology could play a significant role in regulating dysfunctional brain activity.
What we're watching
- Regulatory Approval
- Whether Nexalin can secure FDA approval for its DIFS™ technology based on the expanding body of clinical evidence.
- Market Differentiation
- How Nexalin’s objective imaging data will position it against competitors in the non-invasive brain stimulation market.
- Clinical Expansion
- The pace at which Nexalin can expand its clinical research into additional neurological and psychiatric conditions.
Related topics